DDInter1625 DDInter492
Rubella virus vaccine is a live attenuated virus vaccine for active immunization against rubella (German measles) that is subcutaneously administered. It is prepared from RA 27/3 strain of live attenuated rubella virus. Rubella is a common childhood disease, caused by rubella virus (togavirus).
Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dystrophin gene, which is important for muscle function. This disease can cause serious muscle weakness and progressive breathing and cardiovascular disability, severely impacting patient quality of life and survival.[A179446,A179449,L6697] This disease usually manifests by muscle weakness in early childhood followed by loss of the ability to walk (ambulation) as early as age 7. Deflazacort delays the onset of muscle related complications resulting from DMD, prolonging the lives of children diagnosed with this disease and exerting less harmful effects on the bone health and weight than other steroid medications.[A179452,A25340]
Deflazacort {u} may cause a minor interaction that can limit clinical effects when taken with {v} Isoniazid
Deflazacort {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Esterified estrogens
Deflazacort {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ocrelizumab
Deflazacort {u} may lead to a major life threatening interaction when taken with {v} Cinoxacin
Deflazacort {u} may lead to a major life threatening interaction when taken with {v} Smallpox (Vaccinia) Vaccine, Live
Deflazacort may cause a minor interaction that can limit clinical effects when taken with Isoniazid
Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Esterified estrogens
Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Deflazacort may lead to a major life threatening interaction when taken with Cinoxacin
Deflazacort may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live